Abstract:1088 Background: Adaptive immune resistance (AIR) is pivotal to triple-negative breast cancer (TNBC) progression. Although immune checkpoint inhibitors (ICIs) shed new light on reversing AIR, the treatment effect and predictive markers of immunotherapy remain controversial. The present study focused on epigenetic regulation for TNBC AIR and explored whether this could be clinically targeted. Methods: Through screening an epigenetic gene set in TNBC patients from The Cancer Genome Atlas (TCGA), ARID1A was pinpointed as most significantly correlated with AIR. Humanized immune system (HIS) mice were adopted for TNBC transplantation, identifying CD8+ T cells as most significantly correlated with TNBC ARID1A. To probe the mechanism underlying TNBC ARID1A deficiency-induced CD8+ T cell malfunction and AIR, RNA-seq of both TNBC patients and TNBC cell lines were analyzed and the candidate mediator gene, PD-L1, was identified and verified through western blot, qPCR, IHC, dual luciferase reporter assay and cell co-culture. Chromatin immunoprecipitation and ATAC-seq further demonstrated direct binding of ARID1A to NPM1 promoter to regulate PD-L1 expression. Finally, HIS mice were treated with ICI and the clinical trial CTR20191353 was retrospectively analyzed. Results: Among a series of epigenetic modulators, we first observed that ARID1A, a core subunit of the chromatin remodeling complex SWI/SNF, demonstrated highest correlation with AIR in TNBC patients. This was verified in HIS TNBC mice and a patient cohort from Fudan University Shanghai Cancer Center by higher malignancy observed in ARID1A-deficient TNBC. Both bulk and single-cell RNA-seq in TNBC patients uncovered an immunosuppressive microenvironment induced by TNBC ARID1A deficiency, and CD8+ T cells was identified as the immune cell type most significantly correlated with TNBC ARID1A. CD8+ T cell malfunction and AIR in ARID1A-deficient TNBC was induced by upregulated PD-L1, but ARID1A did not directly regulate PD-L1 expression. We found that ARID1A bound to the NPM1 promoter and that ARID1A deficiency increased NPM1 chromatin accessibility as well as gene expression, further activating PD-L1 transcription. In HIS mice, ICI demonstrated the potential to reverse TNBC ARID1A deficiency-induced AIR manifested by reducing tumor malignancy and activating antitumor immunity. In CTR20191353, a phase 1b clinical trial of pucotenlimab combined with chemotherapy for TNBC, patients with ARID1A deficiency demonstrated significantly better prognosis and the longest progression-free survival was found in ARID1A-low/PD-L1-high group. Conclusions: In AIR epigenetics, TNBC ARID1A deficiency induced AIR via the ARID1A/NPM1/PD-L1 axis, leading to poor outcome. While ARID1A deficiency provided survival advantage for TNBC cells, it simultaneously left the Achilles' heel which could be targeted with ICI.

Influence of Chromatin Remodeling Molecule ARID1A on Metastatic Heterogeneity in Triple Negative Breast Cancer: Binding of YAP

Chromatin Remodelling Molecule ARID1A Determines Metastatic Heterogeneity in Triple-Negative Breast Cancer by Competitively Binding to YAP

HJURP Regulates Cell Proliferation and Chemo-Resistance Via YAP1/NDRG1 Transcriptional Axis in Triple-Negative Breast Cancer

Enhancement of E-cadherin expression and processing and driving of cancer cell metastasis by ARID1A deficiency

ARID1A-mutated cervical cancer depends on the activation of YAP signaling

YAP transduction drives triple-negative breast cancer aggressiveness through modulating the EGFR‒AKT axis in patient-derived xenograft cells

Chromatin accessibility complex subunit 1 enhances tumor growth by regulating the oncogenic transcription of YAP in breast and cervical cancer

RNF181 Modulates Hippo Signaling and Triple Negative Breast Cancer Progression

Knockdown of TAZ Modifies Triple-Negative Breast Cancer Cell Sensitivity to EGFR Inhibitors by Regulating YAP Expression.

ARID1A Mutation in Metastatic Breast Cancer: A Potential Therapeutic Target

Association of ARID1A deficiency with invasive transformation in metastatic bladder cancer.

ARID1A Deficiency Weakens BRG1-RAD21 Interaction That Jeopardizes Chromatin Compactness and Drives Liver Cancer Cell Metastasis.

KMT5A-methylated SNIP1 promotes triple-negative breast cancer metastasis by activating YAP signaling

YAP promotes chromosomal instability by transcriptionally activating AJUBA through its super enhancer in breast cancer

Histone Deacetylase 8 Triggers the Migration of Triple Negative Breast Cancer Cells Via Regulation of YAP Signals.

Abstract 162: ASB13 Inhibits Breast Cancer Progression and Metastasis Through SNAI2 Degradation and Transcriptional Regulation of YAP

YTHDF3 Facilitates Triple-Negative Breast Cancer Progression and Metastasis by Stabilizing ZEB1 Mrna in an M6a-Dependent Manner

Regulation of Hippo Signaling and Triple Negative Breast Cancer Progression by an Ubiquitin Ligase RNF187

A Positive Feedback Loop: RAD18-YAP-TGF-β Between Triple-Negative Breast Cancer and Macrophages Regulates Cancer Stemness and Progression

RNA N 6 -methyladenosine reader YTHDC1 is essential for TGF-beta-mediated metastasis of triple negative breast cancer

ARID1A Deficiency in Triple-Negative Breast Cancer Induces Adaptive Immune Resistance and Sensitivity to Immune Checkpoint Inhibitors.